Olaparib Export Market Intelligence: India's 70 Suppliers Shipping to 49 Countries — TransData Nexus 2026

Q: Who are the top olaparib exporters from India?

The top olaparib exporters from India are: 1. BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED — $285.6K (31.0% market share); 2. SANDOZ PRIVATE LIMITED — $161.9K (17.6% market share); 3. VAMA HEALTH WORLD LLP — $107.6K (11.7% market share); 4. SPECIALITY MEDICINES LIMITED — $76.4K (8.3% market share); 5. SP ACCURE LABS PRIVATE LIMITED — $40.4K (4.4% market share). Together they account for 72.9% of India's total olaparib export value.

Q: What is the total export value of olaparib from India?

The total export value of olaparib from India is $922.2K USD, recorded across 307 shipment transactions from 70 active exporters to 49 destination countries. The average shipment value is $3.0K.

Q: Which countries import olaparib from India?

India exports olaparib to 49 countries worldwide. The top importing countries are: RUSSIA (29.1% share, $268.5K), SLOVENIA (17.6% share, $161.9K), BRAZIL (16.5% share, $152.2K), SWITZERLAND (8.5% share, $78.2K), BAHAMAS (5.5% share, $50.6K). These five markets account for 77.1% of total export value.

Q: What is the HS code for olaparib exports from India?

The primary HS code for olaparib exports from India is 30049099. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) for tracking and reporting pharmaceutical trade flows.

Q: What is the average price of olaparib exports from India?

The average unit price for olaparib exports from India is $683.96 USD per unit, with prices ranging from $0.01 to $9249.59 depending on formulation, packaging, and order volume. The total market is valued at $922.2K across 307 shipments.

Q: Which ports handle olaparib exports from India?

The primary ports for olaparib exports from India are SAHAR AIR CARGO ACC (INBOM4) (39.1% of shipments), SAHAR AIR (18.2% of shipments), HYDERABAD ACC (INHYD4) (5.5% of shipments), Bombay Air Cargo (5.5% of shipments), AHEMDABAD AIR ACC (INAMD4) (5.2% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Q: Why is India a leading exporter of olaparib?

India is one of the world's leading exporters of olaparib due to its large base of 70 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports olaparib to 49 countries, demonstrating 25% global market coverage.

Q: What certifications do Indian olaparib exporters need?

Indian olaparib exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

Q: How many buyers import olaparib from India?

There are 99 registered buyers importing olaparib from India, spread across 49 countries. The repeat buyer rate is 49.5%, indicating strong long-term trade relationships and consistent product quality.

Q: What is the market share of the top olaparib supplier from India?

BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED is the leading olaparib exporter from India with a market share of 31.0% and total export value of $285.6K across 15 shipments. The top 5 suppliers together control 72.9% of total export value.

Suresh Sormare

Olaparib

India Pharmaceutical Trade Intelligence

$922.2K70 Suppliers49 CountriesHS 30049099

ExportsIndia → RUSSIA29.1%India → SLOVENIA17.6%

ImportsPUERTO RICO → India$85.9M UNITED KINGDOM → India$1.4M

#1 Supplier: BDR PHARMACEUTICALS

Olaparib Export Analysis | India Pharmaceutical Trade Intelligence | TransData Nexus

How India Exports Olaparib to the World

Between 2022 and 2026, India exported $922.2K worth of olaparib across 307 verified shipments to 49 countries — covering 25% of world markets in the Advanced Oncology segment. The largest destination is RUSSIA (29.1%). BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED leads with a 31.0% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·

Olaparib export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Olaparib export data snapshot — $922.2K · 70 exporters · 49 countriesTransData Nexus · Indian Customs Data

Top Olaparib Exporters from India

70 active exporters · Ranked by export value

View all 70 →

Top Olaparib Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED	$285.6K	15	2	31.0%
2	SANDOZ PRIVATE LIMITED

Top Countries Importing Olaparib from India

49 destination markets · Ranked by import value

All 49 countries →

Top Countries Importing Olaparib from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	RUSSIA	$268.5K	29.1%
2	SLOVENIA	$161.9K	17.6%
3	BRAZIL	$152.2K	16.5%
4	SWITZERLAND	$78.2K	8.5%
5	BAHAMAS	$50.6K	5.5%
6	UNITED ARAB EMIRATES	$42.8K	4.6%
7	PERU	$40.4K	4.4%
8	PORTUGAL	$11.7K	1.3%
9	MOZAMBIQUE	$11.1K	1.2%
10	TURKEY	$10.9K	1.2%

RUSSIA is India's largest olaparib export destination, absorbing 29.1% of total exports worth $268.5K. The top 5 importing countries — RUSSIA, SLOVENIA, BRAZIL, SWITZERLAND, BAHAMAS — together account for 77.1% of India's total olaparib export value. The remaining 44 destination countries collectively receive the other 22.9%, indicating a focused distribution strategy targeting key markets.

Who Supplies Olaparib to India?

19 origin countries · Total import value: $88.5M

India imports olaparib from 19 countries with a combined import value of $88.5M. The largest supplier is PUERTO RICO ($85.9M, 19 shipments), followed by UNITED KINGDOM and GERMANY. All values are from Indian Customs (DGFT) import records.

Countries Supplying Olaparib to India — Ranked by Import Value
#	Origin Country	Import Value (USD)	Shipments	Share
1	PUERTO RICO	$85.9M	19	97.1%
2	UNITED KINGDOM	$1.4M	7	1.6%
3	GERMANY	$319.0K	9	0.4%
4	UNITED STATES	$263.9K	16	0.3%
5	BRAZIL	$220.2K	5	0.2%
6	CANADA	$194.1K	17	0.2%
7	NETHERLANDS	$24.6K	3	0.0%
8	AUSTRALIA	$16.8K	4	0.0%
9	CHINA	$14.8K	7	0.0%
10	IRELAND	$12.6K	2	0.0%

Showing top 10 of 19 origin countries

PUERTO RICO is the largest supplier of olaparib to India, accounting for 97.1% of total import value. The top 5 origin countries — PUERTO RICO, UNITED KINGDOM, GERMANY, UNITED STATES, BRAZIL — together supply 99.7% of India's olaparib imports. Click any country to see detailed supplier and buyer data for that import corridor.

Regulatory Landscape — Olaparib

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

The U.S. Food and Drug Administration (FDA) initially approved olaparib capsules in December 2014 for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer who had been treated with three or more prior lines of chemotherapy. Subsequently, in August 2017, the FDA granted regular approval to olaparib tablets for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. In December 2018, the FDA expanded the indication to include the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.

As of March 2026, the FDA's Orange Book does not list any approved Abbreviated New Drug Applications (ANDAs) for olaparib, indicating the absence of generic competition in the U.S. market. This exclusivity underscores the importance of understanding the regulatory pathways and market dynamics for potential exporters. The absence of import alerts related to olaparib suggests compliance with FDA standards by current manufacturers.

2EU & UK Regulatory Framework

The European Medicines Agency (EMA) granted marketing authorization for olaparib (Lynparza) on December 16, 2014, for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response to platinum-based chemotherapy. (ema.europa.eu) In September 2022, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved olaparib for the adjuvant treatment of high-risk early-stage breast cancer with inherited BRCA mutations. (icr.ac.uk)

The EMA has also provided product-specific bioequivalence guidance for olaparib, effective from January 1, 2023, outlining the requirements for demonstrating bioequivalence in generic formulations. (ema.europa.eu) Compliance with EU Good Manufacturing Practice (GMP) standards is mandatory for manufacturers exporting to the European Union and the UK.

3WHO Essential Medicines & Global Standards

As of March 2026, olaparib is not listed on the World Health Organization's (WHO) Model List of Essential Medicines. Consequently, it has not undergone WHO Prequalification. However, olaparib's inclusion in major pharmacopoeias such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP) ensures standardized quality specifications for its production and quality control.

4India Regulatory Classification

In India, olaparib is classified under Schedule H of the Drugs and Cosmetics Rules, 1945, indicating that it is a prescription-only medication. The Drug Price Control Order (DPCO) and the National Pharmaceutical Pricing Authority (NPPA) have not set a ceiling price for olaparib as of March 2026, allowing manufacturers to determine pricing. For export purposes, obtaining a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) is mandatory, ensuring compliance with national regulations.

5Patent & Exclusivity Status

Olaparib's primary patents are held by AstraZeneca, with the main patent expected to expire in December 2028. This patent protection currently limits the entry of generic versions into the market. However, the absence of approved ANDAs in the FDA's Orange Book suggests that generic competition may emerge post-patent expiration, potentially impacting market dynamics.

6Recent Industry Developments

In March 2022, the FDA approved olaparib for the adjuvant treatment of high-risk early-stage breast cancer with inherited BRCA mutations, expanding its therapeutic indications. In September 2022, the MHRA granted approval for the same indication in the UK, aligning with the FDA's decision. (icr.ac.uk)

In June 2022, the EMA adopted product-specific bioequivalence guidance for olaparib, effective from January 1, 2023, providing a framework for the development of generic formulations. (ema.europa.eu) These developments reflect the evolving regulatory landscape and the potential for increased market competition in the coming years.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Global Price Benchmark — Olaparib

Retail & reference prices across 9 markets vs. India FOB export price of $683.96/unit

Global Price Benchmark for Olaparib across major pharmaceutical markets
Market	Price (USD/unit)	Currency	Reference
Australia	Approximately $4,970.00	AUD	According to the Pharmaceutical Benefits Scheme (PBS), Olaparib is listed under the General Schedule with a Dispensed Price for Maximum Quantity (DPMQ) of AUD 6,632.44 for a pack of 56 tablets. (pbs.gov.au)
United States	Data not available	USD	Specific pricing information for Olaparib is not publicly disclosed by the FDA.
United Kingdom	Data not available	GBP	The NHS Drug Tariff does not list Olaparib pricing information.
Germany

Supply Chain Risk Assessment — Olaparib

API sourcing, concentration risk, storage requirements, and current alerts

MEDIUM RISK

1API Sourcing & Raw Material Dependency

Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor used in oncology, relies on a complex synthesis process involving multiple key starting materials (KSMs) and intermediates. India, a significant producer of active pharmaceutical ingredients (APIs), often depends on imports for these critical raw materials. Notably, China controls approximately 70–80% of the global KSM supply and 60–70% of intermediates, making it a dominant player in the upstream pharmaceutical supply chain. This heavy reliance on Chinese imports exposes Indian manufacturers to potential supply disruptions.

Historical instances underscore this vulnerability. For example, in July 2018, environmental regulations led to the shutdown of several Chinese chemical plants, causing significant supply shortages and price increases for KSMs and intermediates. These disruptions had a cascading effect on global API production, including in India, highlighting the risks associated with concentrated sourcing.

2Supplier Concentration & Single-Source Risk

Our proprietary trade data from 2022 to 2026 indicates that the top five Indian exporters of Olaparib account for 72.9% of total export value, with BDR Pharmaceuticals International Private Limited leading at 31.0%. This high supplier concentration poses a significant risk; any operational or regulatory issues affecting these key players could disrupt the entire supply chain.

Access Complete Olaparib Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 307 transactions across 49 markets.

Request Demo View Pricing

Frequently Asked Questions — Olaparib Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top olaparib exporters from India?

The leading olaparib exporters from India are BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED, SANDOZ PRIVATE LIMITED, VAMA HEALTH WORLD LLP, and 9 others. BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED leads with 31.0% market share ($285.6K). The top 5 suppliers together control 72.9% of total export value.

What is the total export value of olaparib from India?

The total export value of olaparib from India is $922.2K, recorded across 307 shipments from 70 active exporters to 49 countries. The average shipment value is $3.0K.

Which countries import olaparib from India?

India exports olaparib to 49 countries. The top importing countries are RUSSIA (29.1%), SLOVENIA (17.6%), BRAZIL (16.5%), SWITZERLAND (8.5%), BAHAMAS (5.5%), which together account for 77.1% of total export value.

What is the HS code for olaparib exports from India?

The primary HS code for olaparib exports from India is 30049099. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Olaparib

Olaparib

Top Olaparib Exporters from India

Top Countries Importing Olaparib from India

Who Supplies Olaparib to India?

Quick Facts

Related Advanced Oncology

Related Analysis

Need Details?

Regulatory Landscape — Olaparib

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Global Price Benchmark — Olaparib

Supply Chain Risk Assessment — Olaparib

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Olaparib Trade Intelligence

Frequently Asked Questions — Olaparib Exports from India

Who are the top olaparib exporters from India?

What is the total export value of olaparib from India?

Which countries import olaparib from India?

What is the HS code for olaparib exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

India Cost Advantage

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of olaparib exports from India?

Which ports handle olaparib exports from India?

Why is India a leading exporter of olaparib?

What certifications do Indian olaparib exporters need?

How many buyers import olaparib from India?

What is the market share of the top olaparib exporter from India?

Analysis Methodology